Jay Shepard
Known title: DirectorCIK: 0001587788
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
INO: PGEN AdenoVerse Pipeline May Drive Growth Beyond Papzimeos. The article examines whether PGEN’s AdenoVerse platform can generate growth that surpasses the company’s current Papzimeos product line. It highlights the potential of the pipeline to broaden Inovio’s therapeutic offerings. The discussion comes as the stock sits near its 16‑touch support level of $1.07 and a neutral RSI of 45.6. Analysts still target the shares at around $3.17 on average.
Transaction History
| IRWD | ▲ Buy | Grant | 63,481 | $0 | 6/16/2026 | View on chart |
| IRWD | ▲ Buy | Grant | 45,000 | $0 | 6/10/2025 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,167 | — | 5/21/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 24,311 | $0 | 6/18/2024 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,166 | — | 5/15/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 22,350 | $0 | 6/20/2023 | View on chart |
| INO | ▲ Buy | Option Exercise | 19,000 | — | 5/16/2023 | View on chart |
| INO | ▲ Buy | Option Exercise | 4,273 | — | 1/15/2023 | View on chart |
| IRWD | ▲ Buy | Grant | 21,571 | $0 | 6/1/2022 | View on chart |
| INO | ▲ Buy | Option Exercise | 18,000 | — | 5/13/2022 | View on chart |
| INO | ▲ Buy | Option Exercise | 4,274 | — | 1/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Ironwood Pharmaceuticals names Tammi Gaskins as CEO
Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.
Ironwood Pharmaceuticals names Tammi Gaskins as CEO. Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.